SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Tremfya™ (guselkumab) Injection

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

ATTENTION: Tremfya IV induction (loading dose) for treatment of ulcerative colitis or Crohn's disease can only be billed under the **MEDICAL BENEFIT**. NDC: 57894-0650-01/02: J1628; 200 mg/20 mL= 200 billable units

Recommended Dosage:

Indication	Dosage
❑ **Moderate-to-Severe Plaque Psoriasis** – who are candidates for systemic therapy or phototherapy	• 100mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter
❑ **Active Psoriatic Arthritis**	• 100mg administered by subcutaneous injection at Week 0, Week 4 then every 8 weeks

(Continued on next page)

Indication	Dosage
❑ **Moderate-to-Severe active ulcerative colitis (Adults)**	• 200 mg IV induction dose at weeks 0, 4, & 8 by an HCP, recommended maintenance dosage is 100 mg SC at week 16 and every 8 weeks thereafter, or 200 mg SC at week 12 and every 4 weeks thereafter
❑ **Moderate-to-Severe active Crohn's disease (Adults)**	• 200 mg IV or 400mg SC induction dose at weeks 0, 4, & 8, recommended maintenance dosage is 100 mg SC at week 16 and • every 8 weeks thereafter, or 200 mg SC at week 12 and every 4 weeks thereafter

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ DIAGNOSIS: Moderate-to-Severe Chronic Plaque Psoriasis

- ❑ Moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- ❑ Member is 6 years of age or older weighing at least 40 kg
- ❑ Diagnosis of moderate to severe plaque psoriasis for ≥ 6 months with ≥ 1 of the following:
  - ❑ Affected body surface area (BSA) of ≥ 10%
  - ❑ Psoriasis Area and Severity Index (PASI) score ≥ 10
  - ❑ Incapacitation due to plaque location (e.g., head and neck, palms, soles or genitalia)
- ❑ Member is not receiving guselkumab in combination with another biologic agent for psoriasis or non-biologic immunomodulator (e.g., apremilast, tofacitinib, baricitinib)
- ❑ Trial and failure of **TWO (2)** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

❑ DIAGNOSIS: Active Psoriatic Arthritis

- ❑ Member has a diagnosis of active psoriatic arthritis
- ❑ Member is 6 years of age or older weighing at least 40 kg
- ❑ Trial and failure of **TWO (2)** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

(Continued on next page)

❑ DIAGNOSIS: Moderate-to-Severe Ulcerative Colitis (UC)

- ❑ Member has a diagnosis of moderate to severe ulcerative colitis
- ❑ Member is 18 years of age or older
- ❑ Member is not receiving guselkumab in combination with another biologic agent for UC or non-biologic immunomodulator (e.g., upadacitinib)
- ❑ Member has tried and failed **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

❑ DIAGNOSIS: Moderate-to-Severe Crohn's Disease (CD)

- ❑ Member has a diagnosis of moderate to severe Crohn's disease
- ❑ Member is 18 years of age or older
- ❑ Trial and failure to of a compliant regimen of corticosteroids or immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate)
- ❑ Member is not receiving guselkumab in combination with another biologic agent for CD or non-biologic immunomodulator (e.g., upadacitinib)
- ❑ Member has tried and failed **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

❑ Induction Dose (If required) – One time approval for duration of 2 months, member to receive up to three (3) IV infusion doses

Authorization Criteria: To be reviewed for one-time approval under the medical benefit

- ❑ Medication will be used as induction therapy
- ❑ Medication being provided by:
  - ❑ Location/site of drug administration: _____
  - ❑ NPI or DEA # of administering location: _____
- ❑ Member to receive FDA approved loading dose of 200mg administered by intravenous infusion over at least 1 hour at Week 0, Week 4, and Week 8

Medication being provided by Specialty Pharmacy - PropriumRx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

REVISED/UPDATED/REFORMATTED: ~~10/31/2018; 11/4/2018; 11/18/2018; 4/6/2019; 12/17/2019; 11/23/2020; 12/21/2020; 7/19/2021; 7/11/2022; 6/19/2023 11/15/2023; 12/13/2024,3/25/2025; 6/20/2025, 10/17/2025; 12/15/2025, 2/24/2026; 3/11/2026;~~ **7/13/2026**